Hamilton Discusses the Role of PARP Inhibition in Advanced Ovarian Cancer
October 18th 2022During a Targeted Oncology case-based roundtable event, Chad Hamilton, MD, broke down the data that shows how the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer is impacting patients.
Dowlati Compares the Advantages and Disadvantages of Atezolizumab and Durvalumab in ES-SCLC
October 17th 2022During a Targeted Oncology case-based roundtable event, Afshin Dowlati, MD, discussed the data supporting the use of atezolizumab and durvalumab as therapy for patients with small cell lung cancer.
Discussing Real-World Experience Using Lenvatinib in Advanced RCC
October 14th 2022During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed with participants their experiences using lenvatinib in treatment of advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Roundtable Discussion: Genetic Testing and Treatment in NSCLC With EGFR 19 Exon Deletion
October 13th 2022During a Targeted Oncology case-based roundtable event, Rachel E. Sanborn, MD, discussed with participants the case of a patient with metastatic lung adenocarcinoma with potential targetable biomarkers.
Recommended Approaches to Treatment for Early-Stage HER2+ Breast Cancer
October 13th 2022During a Targeted Oncology case-based roundtable event, Jennifer M. Matro, MD, discussed the data supporting systemic therapies for treatment of early-stage HER2-positive breast cancer including trastuzumab and pertuzumab.
Roundtable Discussion: Examining Treatment Options After Adjuvant Chemotherapy for TNBC
October 10th 2022During a case-based roundtable event, Christos Vaklavas, MD moderated a discussion about treatment option for a 48-year-old woman with triple negative breast cancer following adjuvant chemotherapy.
Roundtable Discussion: Neal Discusses Molecular Testing and Treatment for EGFR Exon 20+ Lung Cancer
October 6th 2022During a case-based roundtable event, Joel W. Neal, MD, PhD of Stanford Cancer Institute and a group of peers discussed using molecular testing to detect an EGFR exon 20 insertion in a patient with lung cancer.
The Role of Maintenance Daratumumab in Transplant-Eligible Multiple Myeloma
October 5th 2022During a live virtual event, Brea C. Lipe, MD, discussed with participants their experiences with maintenance treatment in patients with transplant-eligible multiple myeloma. This is the second of 2 articles based on this event.
Comparing Physician Experience With Trial Data for Frontline RCC Regimens
October 3rd 2022During a live virtual event, Sumanta K. Pal, MD, discussed with participants how their experience with immunotherapy and tyrosine kinase inhibitor therapies aligned with the data from pivotal clinical trials. This is the second of 2 articles based on this event.
Roundtable Discussion: Hamilton Compares Therapy Options and Sequencing for Recurrent TNBC
September 25th 2022During a Targeted Oncology case-based roundtable event, Erika P. Hamilton, MD, discussed the choice of first- and second-line therapy for a patient with triple-negative breast cancer following adjuvant chemotherapy.
Lee Reviews Trials Supporting IO/TKI Combinations in Frontline RCC
September 23rd 2022During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the latest data supporting the use of lenvatinib/pembrolizumab as frontline therapy for patients with advanced clear cell renal cell carcinoma.